AL
ALLR.US Allarity Therapeutics Inc
- Market cap
- USD 15.2M
- P/E
- -
- P/B
- 4.11x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ALLR.US undervalued?
Graham numberThe Graham number of Allarity Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Allarity Therapeutics Inc fundamental analysis
No fundamental analysis for Allarity Therapeutics Inc yet.
Allarity Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Allarity Therapeutics Inc
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PAR…
Full company profileAllarity Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Allarity Therapeutics Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 143K | 1.46M | 1.46M | 120K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 320K | 40.0K |
| Gross Profit | 143K | -761K | -3.62M | 120K | -86.0K | -106K | -120K | -37.0K | -9.00K | 320K | - |
| Operating Income | -4.49M | -3.84M | -4.98M | -17.6M | -8.32M | -26.6M | -34.5M | -17.1M | -27.2M | -12.6M | -14.5M |
| EBITDA | -4.21M | -3.83M | -4.90M | -15.6M | -6.05M | -25.8M | -17.3M | -11.3M | -24.2M | -11.0M | -13.5M |
| Net Income | -3.68M | -4.90M | -2.29M | -14.3M | -6.60M | -26.6M | -16.1M | -11.9M | -24.5M | -11.2M | -16.5M |
| EPS | -946,717 | -1,259,060 | -589,282 | -3,679,434 | -1,697,172 | -3,520,211 | -1,416,049 | -3,516 | -15 | -0.78 | -1.03 |
| Balance Sheet | |||||||||||
| Total Assets | 6.54M | 2.09M | 38.6M | 31.6M | 33.4M | 49.6M | 14.5M | 11.9M | 22.7M | 18.3M | 27.2M |
| Total Liabilities | 1.34M | 1.70M | 10.7M | 10.7M | 6.55M | 30.8M | 12.7M | 14.6M | 10.8M | 8.43M | 29.5M |
| Shareholders' Equity | 5.20M | 394K | 27.9M | 20.9M | 26.9M | 18.8M | 1.89M | -2.75M | 11.8M | 9.83M | -2.26M |
| Cash & Short-term Investments | 2.07M | 536K | 237K | 1.52M | 298K | 19.9M | 2.03M | 166K | 19.5M | 14.7M | 14.1M |
| Total Debt | - | - | 2.90M | 963K | 1.79M | 1.09M | 3.74M | 1.30M | 1.35M | 1.40M | 23.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.98M | -1.34M | -4.24M | -10.1M | -7.25M | -15.1M | -16.8M | -12.7M | -17.4M | -14.8M | -13.2M |
| Capital Expenditure | 77.8K | 37.0K | 5.68K | 8.00K | 3.00K | 18.0K | 18.0K | 0.00 | 298K | 8.00K | 85.3K |
| Free Cash Flow | -4.06M | -1.34M | -4.24M | -10.1M | -7.25M | -15.1M | -16.8M | -12.7M | -17.7M | -14.8M | -13.3M |
| Ratios | |||||||||||
| ROE | -70.8% | -1,242.9% | -8.2% | -68.5% | -24.6% | -141.9% | -849.6% | - | -207.6% | -114.3% | - |
| ROA | -56.3% | -234.0% | -5.9% | -45.3% | -19.8% | -53.7% | -110.4% | -100.3% | -108.2% | -61.5% | -60.5% |
| Net Profit Margin | -2,570.4% | -335.7% | -157.0% | -11,927.5% | - | - | - | - | - | -3,509.7% | -41,183.3% |
| Debt to Equity | - | - | 0.10x | 0.05x | 0.07x | 0.06x | 1.98x | - | 0.11x | 0.14x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Allarity Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 11.0M | 3,248 | - |
| 2022 | USD 1.51M | 133,245 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:30 on Sep 11, 2024.
Who owns Allarity Therapeutics Inc
- Insiders 0.47%
- Institutions 7.53%
- Public & others 92.00%
- Shares outstanding 15.9M
- Free float 15.8M
Top funds holding ALLR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 82.1K | 0.52% | -0.38% | Sep 2026 |
| Fidelity Total Market Index | 22.2K | 0.14% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 21.6K | 0.14% | 0.00% | Sep 2026 |
Top institutions holding ALLR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Renaissance Technologies Corp | 332K | 2.08% | +45.35% | Jun 2026 |
| Vanguard Capital Management, LLC | 172K | 1.08% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 155K | 0.97% | -18.66% | Jun 2026 |
| State Street Corp | 138K | 0.86% | 0.00% | Jun 2026 |
| Militia Capital Management, LLC | 99.0K | 0.62% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 91.7K | 0.58% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 74.9K | 0.47% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 37.0K | 0.23% | 0.00% | Jun 2026 |
| Northern Trust Corp | 36.5K | 0.23% | -24.05% | Jun 2026 |
| Jane Street Group LLC | 36.0K | 0.23% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 27.5K | 0.17% | 0.00% | Jun 2026 |
| UBS Group AG | 26.6K | 0.17% | +14.82% | Jun 2026 |
| XTX Topco Ltd | 20.9K | 0.13% | -27.90% | Jun 2026 |
| Susquehanna International Group, LLP | 17.2K | 0.11% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 15.3K | 0.10% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 2.65K | 0.02% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 22.00 | 0.00% | +2,100.00% | Jun 2026 |
| FMR Inc | 13.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 1.00 | 0.00% | 0.00% | Jun 2026 |
Allarity Therapeutics Inc company profile
- Company name
- Allarity Therapeutics Inc
- Ticker
- ALLR.US
- Exchange
- USA Stocks
- Listed since
- Dec 21, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- 123 E. Tarpon Ave., Tarpon Springs, FL, United States, 34689
- Phone
- 401 426 4664
- Website
- allarity.com
About Allarity Therapeutics Inc
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
Allarity Therapeutics Inc management
5- Mr. Thomas H. JensenFounder, CEO & Director · born 1978
- Dr. Jeremy R. Graff Ph.D.President & Chief Development Officer · born 1970
- Dr. Steen Meier Knudsen Ph.D.Founder & Chief Scientific Officer · born 1961
- Mr. Jeffrey S. Ervin M.B.A.Chief Financial Officer · born 1977
- Dr. Jose L. Iglesias M.D.Consultant Chief Medical Officer · born 1957